Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: A preclinical study

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Røe, Kathrine ^a,b   Kakar, Manish ^a   Seierstad, Therese ^a   Ree, Anne H ^b,c   Olsen, Dag R ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Androgen deprivation therapy; Artificial neural network; Back propagation neural network; Diffusion weighted magnetic resonance imaging; Dynamic contrast enhanced magnetic resonance imaging; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; CONTRAST MEDIUM; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; ARTIFICIAL NEURAL NETWORK; BACK PROPAGATION; CANCER RADIOTHERAPY; CANCER SIZE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEASIBILITY STUDY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MOUSE; NONHUMAN; NONLINEAR SYSTEM; PREDICTION; PROSTATE CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DIFFUSION; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PROSTATE TUMOR; RADIOTHERAPY;

ANDROGENS; ANIMALS; CONTRAST MEDIA; DIFFUSION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEURAL NETWORKS (COMPUTER); PROSTATIC NEOPLASMS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79958043474     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-65     Document Type: Article

References (25)

1. Mitchell RE, Chang SS. Current controversies in the treatment of high-risk prostate cancer. Curr Opin Urol 2008, 18:263-268. 10.1097/MOU.0b013e3282f9b37f, 18382235.
2. Barry MJ. Screening for prostate cancer--the controversy that refuses to die. N Engl J Med 2009, 360:1351-1354. 10.1056/NEJMe0901166, 19297564.
3. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003, 45:169-184. 10.1016/S0720-048X(02)00303-0, 12595101.
4. Koh DM, Padhani AR. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006, 79:633-635. 10.1259/bjr/29739265, 16793851.
5. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S, 10508281.
6. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007, 8:63-74. 10.1016/S1470-2045(06)71012-9, 17196512.
7. Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR. Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia 2007, 9:392-400. 10.1593/neo.07154, 1877980, 17534444.
8. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004, 6:831-837. 10.1593/neo.03343, 1531687, 15720810.
9. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005, 102:5524-5529. 10.1073/pnas.0501532102, 555936, 15805192.
10. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248:894-900. 10.1148/radiol.2483071407, 18710982.
11. Kakar M, Seierstad T, Røe K, Olsen DR. Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts. Int J Radiat Oncol Biol Phys 2009, 75:506-511. 10.1016/j.ijrobp.2009.05.036, 19735875.
12. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008, 190:1180-1186. 10.2214/AJR.07.2924, 18430829.
13. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008, 18:71-77. 10.1097/MOU.0b013e3282f19d01, 2804482, 18090494.
14. Lisboa PJ, Taktak AF. The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw 2006, 19:408-415. 10.1016/j.neunet.2005.10.007, 16483741.
15. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl 2004, 86:334-338. 1964229, 15333167.
16. Rumelhart DE, Hinton GE, Williams RJ. Learning representations by back-propagating errors. Nature 1986, 323:533-536.
17. Gulliford SL, Webb S, Rowbottom CG, Corne DW, Dearnaley DP. Use of artificial neural networks to predict biological outcomes for patients receiving radical radiotherapy of the prostate. Radiother Oncol 2004, 71:3-12. 10.1016/j.radonc.2003.03.001, 15066290.
18. Gamito EJ, Crawford ED. Artificial neural networks for predictive modeling in prostate cancer. Curr Oncol Rep 2004, 6:216-221. 10.1007/s11912-004-0052-z, 15066233.
19. Tewari A, Issa M, El-Galley R, Stricker H, Peabody J, Pow-Sang J, Shukla A, Waisman Z, Rubin M, Wei J, Montie J, Demers R, Johnson CC, Lamerato L, Divine GW, Crawford ED, Gamito EJ, Farah R, Naravan P, Carlson G, Menon M. Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 2001, 5:163-169. 10.1089/10915360152745849, 11790278.
20. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, Hakama M, Rannikko S, Tammela TL, Stenman U. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000, 56:418-422. 10.1016/S0090-4295(00)00672-5, 10962306.
21. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69:198-207. 10.1002/pros.20872, 18942119.
22. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia 2010, 12:818-825. 2950331, 20927320.
23. Seierstad T, Røe K, Høvik B. Construction of a modified capacitive overlap MR coil for imaging of small animals and objects in a clinical whole-body scanner. Phys Med Biol 2007, 52:N513-N522. 10.1088/0031-9155/52/22/N02, 17975281.
24. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994, 31:567-571. 10.1002/mrm.1910310516, 8015413.
25. Geman S, Bienenstock E, Doursat R. Neural networks and the bias/variance dilemma. Neural Comput 1992, 4:1-58.